Balistreri
Balistreri v. Boehringer Ingelham Pharmaceuticals, Inc.
Opinion
Trial Court Opinion
I IE EI NEI EI AES RITE ES NEE eID INOEIGG ENNIS NEED NE
«ES DIST, Certified to be a true ar LS aes op correct copy of the documer fa & td Angela E. Noble, Cle UNITED STATES JUDICIAL PANEL |/ ae Mi □□□□□□□□□□□□□□ on 2 Kale By___ Patrick Edward! a □ epu MULTIDISTRICT LITIGATION pe SY one Feb 6 202
IN RE: ZANTAC (RANITIDINE)
PRODUCTS LIABILITY LITIGATION MDL No. 2924
TRANSFER ORDER
Before the Panel: Plaintiffs in five actions listed on Schedule A’ move under 28 U.S.C. § 1407 to centralize pretrial proceedings in the actions listed on Schedule A in the District of New Jersey or, alternatively, the Southern District of Florida. This litigation consists of fifteen actions pending in nine districts. Plaintiffs in all of the actions allege that the heartburn medication Zantac—and specifically the ranitidine molecule, its active ingredient—breaks down to form an alleged carcinogen known as N-Nitrosodimethylamine (NDMA). Nine of these actions are brought by individual plaintiffs asserting personal injury claims. Six are brought on behalf of putative classes of…